おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
Noxxon Pharma
company
About
Noxxon Pharma develops biostable aptamers and substances based on mirror image nucleic acids.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- €1M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 1998
- Number Of Employee
- 51 - 100
- Operating Status
- Active
NOXXON Pharma AG, a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
€2.20M
Noxxon Pharma has raised a total of
€2.20M
in funding over 2 rounds. Their latest funding was raised on
Mar 3, 2021 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 3, 2021 | Post-IPO Equity | €1.20M | 1 | — | — | Detail |
| May 2, 2017 | Post-IPO Debt | €1M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Noxxon Pharma is funded by 1 investors.
Kreos Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Kreos Capital
|
— | Post-IPO Equity |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
